immutep (asx:imm, nasdaq:immp) receives fast track designation from fda - october 12, 2022
Published 1 year ago • 230 plays • Length 5:42
Download video MP4
Download video MP3
Similar videos
-
15:49
immutep (asx:imm) - webinar presentation
-
7:17
immutep (asx:imm, nasdaq:immp) delivering strong data in first-line non-small cell lung cancer
-
4:44
immutep (asx:imm, nasdaq:immp) - innovative cancer therapies
-
7:09
immutep (asx:imm, nasdaq:immp) reports 71.4% response rate for lung cancer therapy, october 31, 2023
-
6:03
immutep (asx:imm, nasdaq:immp) reports positive discussions with the fda and strong survival data
-
6:25
immutep (asx:imm, nasdaq:immp) discusses a transformative year for lag-3 therapies
-
52:08
immutep (asx:imm, nasdaq:immp) global webcast presentation at sitc 2022
-
46:43
immutep limited (asx:imm, nasdaq:immp) - webcast presentation for cohort b of tacti-003 trial
-
1:16:07
webinar: how to invest in us & hk etfs from rm100 per month
-
17:00
fsmone mid-year review 2024: malaysia equities - capitalizing on external drivers
-
56:38
immutep (asx:imm, nasdaq:immp) webcast for tacti-002 data presented at asco 2022 - 10 jun 2022
-
7:43
immutep (asx:imm; nasdaq: immp) company update on start of 2021
-
4:19
immutep (asx:imm) clinical trial update
-
47:53
immutep (asx:imm, nasdaq:immp) tacti-003 results, june 2024
-
4:32
immutep (asx:imm) company update
-
10:01
immutep limited (asx:imm, nasdaq:immp) encouraging results for immutep's cancer therapies
-
3:33
immutep (asx:imm) reports positive trial data
-
5:10
immutep (asx:imm, nasdaq:immp) reports first subject dosed in autoimmune disease study
-
50:22
immutep (asx:imm, nasdaq:immp) esmo congress results webinar, 23 october 2023
-
16:06
immutep (asx:imm) - webinar presentation
-
31:08
immutep (asx:imm) 2023 agm - ceo presentation
Clip.africa.com - Privacy-policy